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Dear Editor,
The beneficial effects of a direct thrombin inhibitor dabigatran
etexilate (DE) on the development and stability of atheroscle-
rotic lesions in apolipoprotein E deficient mice was studied by
Kadoglou et al. and was recently published [1].
We fail to understand why the authors chose to administer
DE to the mice by mixing it with chow. The preferred method
for oral administration of drug to animals is by gavage so that
the exact amount of drug given can be calculated [2]. When a
specific amount of drug is mixed with a known quantity of
chow, the amount of drug consumed can be easily calculated
from the chow left over. However one cannot be sure about
the amount of DE consumed by each animal, as there is a
possibility of wide variation and inadequate amount of drug
consumption and mice can spit or spill some amount of
consumed chow. Although these issues might result in a trivial
discrepancy only, they gain significance in small animals like
mice. So it is a good practice to administer drugs by gavage to
small animals. No justification was given by authors for their
preference of this method over gavage.
In any study to evaluate efficacy, monitoring of adverse
events is an essential component. There is no mentioning of
bleeding complications in mice with DE. Even if the authors
did not encounter any such events during the study, this
needs to be mentioned in the results section.
‘All tables should stand alone’ is the golden rule of
presenting data in tabular form [3]. This rule is not followed
in the published article. In table 1, the units for various
parameters are not mentioned. Some of these parameters like
plasma glucose can be expressed in different units (mg/dl or
mmol/L) and the magnitude of the parameters differs con-
siderably with the change in units. Hence without units the
value can be blown out of proportion and this is a dangerous
omission.
Despite these slips, the article in my opinion did contrib-
ute to understanding the role of thrombin in atherosclerotic
progression.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Kadoglou NP, Moustardas P, Katsimpoulas M, Kapelouzou A,
Kostomitsopoulos N, Schafer K, et al. The beneficial effects of a
direct thrombin inhibitor, dabigatran etexilate, on the development
and stability of atherosclerotic lesions in apolipoprotein E-deficient
mice. Cardiovasc Drugs Ther. 2012;26:367–74.
2. Mayer D. General toxicity. In: Vogel HG, Hock FJ, Mass J, Mater D,
editors. Drug discovery and evaluation: Safety and pharmacokinetic
assays. 1st ed. Berlin: Springer-Verlag publication; 2006. p. 782.
3. Priebe HJ. The results. In: Hall GM, editor. How to write a paper. 3rd
ed. London: BMJ publication; 2004. p. 26.
Editorial Note
Despite several requests to the authors (Kadoglou et al.) to respond to
this Letter to the Editor, no such response was received.
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